Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure.

AIDS research and human retroviruses - 10 Aug 2002

Antinori Andrea, Zaccarelli Mauro, Cingolani Antonella, Forbici Federica, Rizzo Maria G, Trotta Maria P, Di Giambenedetto Simona, Narciso Pasquale, Ammassari Adriana, Girardi Enrico, De Luca Andrea, Perno Carlo F

Abstract excerpt

Heterogeneity in genotype mutations associated with resistance of HIV to nonnucleoside reverse transcriptase inhibitors (NNRTIs) should allow identification of patients failing nevirapine (NVP) who might benefit from efavirenz (EFV)-containing salvage regimens. To establish the feasibility of recycling EFV after failure of NVP-containing regimens genotypic data on 103 NVP-failed patients were analyzed to evaluate...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alkynes
Share to Benzoxazines

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cyclopropanes

Share to Drug Resistance, Microbial

Share to HIV Infections

Share to Nevirapine

Share to Oxazines

Share to Reverse Transcriptase Inhibitors

Source

Identifiers

PMID: 12201905
DOI: 10.1089/08892220260190308

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure.PMID 12201905Read ↗

Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen.Semantic proximity Read ↗

Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimen.Semantic proximity Read ↗

Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA.Semantic proximity Read ↗

Detection of Minority Populations of HIV-1 Expressing the K103N Resistance Mutation in Patients Failing NevirapineSemantic proximity Read ↗

Nonnucleoside Reverse Transcriptase Inhibitor ResistanceSemantic proximity Read ↗

Broad phenotypic cross-resistance to elvitegravir in HIV-infected patients failing on raltegravir-containing regimens.Semantic proximity Read ↗

Efavirenz: resistance and cross-resistance.Semantic proximity Read ↗

Genotypic resistance profile in treatment-experienced HIV-infected individuals after abacavir and efavirenz salvage regimen.Semantic proximity Read ↗

Genotypic and phenotypic nevirapine resistance correlates with virological failure during salvage therapy including abacavir and nevirapine.Semantic proximity Read ↗

The rate of accumulation of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance in patients kept on a virologically failing regimen containing an NNRTI*.Semantic proximity Read ↗

Persistence of earlier HIV-1 drug resistance mutations at new treatment failure.Semantic proximity Read ↗

Role of low-frequency HIV-1 variants in failure of nevirapine-containing antiviral therapy in women previously exposed to single-dose nevirapine.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.